CClinicalTrials.gg
CompletedNCT00487448FLAG-IDAUpdated Nov 19, 2008

SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia

A Phase 4 interventional study of Fludarabine and Cytarabine in Myelodysplastic Syndrome and Acute Myeloblastic Leukemia, sponsored by PETHEMA Foundation. Completed at 15 sites in Spain. Open to participants aged Up to 75 Years. Per ClinicalTrials.gov, last updated 2008-11-19.

Sponsored by PETHEMA Foundation · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
Up to 75 Years
Sex
All
01

Study summary

Association group of therapeutic specialities authorized in a remission induction treatment(FLAG-IDA: fludarabine, cytarabine, G-CSF (lenograstim) and idarubicin) and an intensive postremission treatment with authorized therapeutic association specialities and with/without Autologous Hemopoietic Stem Cell Transplantation or Bone Marrow Transplantation in Patients With High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia.

Read the detailed description

To reach the first remission, the patients receive one cycle of FLAG-IDA combination, that include: Fludarabine 30 mg/m 2 /d Days 1 to 4 in IV perfusion during 30 minutes; Cytarabine 2 g/m 2/d, days 1 to 4 in IV perfusion during 4 hours glycosylate G-CSF 300 µg/m 2/d, days -1 to 5 SC; lenograstim 263 µg/d f, days 11 until absolute neutrophil count >1x10 9 /L SC; Idarubicin 10 mg/m2/d, days 1 to 3 IV bolus (15 minutes)

Patients who don't reach complete remission (CR) are considered as a failure and must go out of study.

The participating centres should decide if the patients under 35 years in CR and with unrelated donor, are excluded to be treated with allogenic transplantation or they continue in the study.

The patients who reach CR will receive one consolidation cycle with IDA-ARAC + G-CSF combination:

Idarubicin 10 mg/m2/d, days 1 to 3 IV bolus (15 minutes); Cytarabine 200 mg/m 2/d days 1 to 5 IV in 24 hours continuous perfusion; glycosylate G-CSF(lenograstim) 263 µg, days 12 until absolute neutrophil count >1x10 9 /L SC

The patients younger than 65 years that is possible, will done an autologous transplantation with peripheral stem blood cells or combined with peripheral stem blood cells and bone marrow stem cells. The preparative regimen recommended are BuCy2 (busulfan-cyclophosphamide) and ICT-Cy (irradiation corporal total-cyclophosphamide).

The patients older than 65 years will receive one intensification cycle with carboplatin and G-CSF.

The peripheral blood stem cells collection should be done during the recuperation period after consolidation chemotherapy in patients under 65 years. The leucapheresis procedure could be determinate for in each center participating.

The patients with no sufficient collection of stem cells during the regeneration period post-chemotherapy of consolidation, will receive glycosylate G-CSF (lenograstim, Granocyte®)10 µg/kg/d SC during 5 days, doing the collection cells on days 5 and 6. In the situations that the peripheral blood stem cells are non satisfactory, will realize a collection of bone marrow stem cells.

The realization of Peripheral Blood Stem Cell Transplantation or combined, depends the number of cells obtained in the collection procedures.In the situations that didn't reach sufficient number of cells (peripheral blood and bone marrow), should be administered one chemotherapy intensification cycle.

The preparative regimen is established by each participating center, but is recommended one of next:

  1. BuCy2 (busulfan 16 mg/kg follow by cyclophosphamide 120 mg/kg),
  2. Total-body irradiation 12 Gy and cyclophosphamide 120 mg/kg.

Intensification treatment:

Patients older than 65 years and younger than 65 who the collection cells for transplantation is not enough, will receive one cycle of intensification chemotherapy with carboplatin and glycosylate G-CSF:

Carboplatin 300 mg/m2/d days 1 to 4 IV in 24 hours continuous perfusion glycosylate G-CSF (lenograstim)263 µg f days 11 until absolute neutrophil count >1x10 9 /L, SC

02

Conditions studied

  • Myelodysplastic Syndrome
  • Acute Myeloblastic Leukemia

Keywords

  • Myelodysplastic Syndrome
  • Chemotherapy
  • Peripheral blood stem cells transplantation
  • Bone marrow transplantation
  • Secondary Acute Myeloblastic Leukemia
03

In context

Leukemia

5,441 studies on the registry are indexed under Leukemia; 637 are open to participants now.

This study's planned enrollment of 200 is above the median of 38 across 4,248 interventional studies indexed under Leukemia.

Browse Leukemia studies →

Lead sponsor

PETHEMA Foundation is the lead sponsor of 104 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age \< 75 years
  • Diagnosis of Myelodysplastic Syndrome in order to FAB criteria, excluding patients with chronic myeloid leukemia.
  • IPI > 1 (High risk or Intermedia risk-2) and/or IPE equal or > 3 (High risk o Intermedia risk) or secondary acute myeloid leukemia.
  • Resolved toxicity for previous treatments received to Myelodysplastic Syndrome .
  • Myelodysplastic Syndrome de novo.

Exclusion criteria

Exclusion Criteria:

  • Associated neoplasia.
  • Chronic disease that can limit the patient follow up protocol (cardiovascular disease, active infection uncontrolled, etc.).
  • Age \< 55 years with related donor HLA compatible.
  • Use an investigational drug in the 30 previous days.
  • Previous treatment with chemotherapy agents.
  • Simultaneous treatment during the study with other drugs not allowed in the protocol.
  • Bilirubin > 2 mg/dL and GPT >2 times the normal value.
  • Creatinine > 2 mg/dL.
  • Hypersensibility to agents used in the protocol.
  • Secondary MDS to chemo-radiotherapy .
  • HIV positive.
  • Chronic myeloblastic leukemia
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Interventions

  • DrugFludarabine
  • DrugCytarabine
  • DrugG-CSF
  • DrugIdarubicin
  • ProcedurePeripheral blood stem cell transplantation
  • ProcedureBone marrow transplantation
06

What researchers measure

Primary outcomes

  1. Evaluation of efficacy of study treatment: complete remission rate, remission duration and global survival

    Time frame: 2 years

Secondary outcomes

  1. Evaluation of neutropenia and thrombocytopenia duration post-induction chemotherapy

    Time frame: 3 months

  2. Determinate the percentage of patients that reach the transplantation

    Time frame: 3 months

  3. Determinate the toxicity of induction regimen and the chemotherapy postremission

    Time frame: 1 year

07

Study locations

15 sites
  • Hospital de la Ribera
    Alzira, Spain
  • Hospital Germans Trias i Pujol
    Badalona, Spain
  • Hospital del Mar
    Barcelona, Spain
  • Hospital Vall d'Hebron
    Barcelona, Spain
  • Hospital Puerta del Mar
    Cadiz, Spain
  • Hospital del SAS
    Jerez de la Frontera, Spain
  • Hospital de Leon
    Leon, Spain
  • Hospital Clínico San Carlos
    Madrid, Spain
  • Hospital Universitario La Paz
    Madrid, Spain
  • Hospital Morales Messeguer
    Murcia, Spain
  • Hospital Central de Asturias
    Oviedo, Spain
  • Hospital Clínico de Salamanca
    Salamanca, Spain
  • Hospital Arnau de Vilanova
    Valencia, Spain
  • Hospital Dr. Pesset
    Valencia, Spain
  • Hospital Universitario La Fe
    Valencia, Spain
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 19, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00487448
Lead sponsor
PETHEMA Foundation
First posted
Jun 18, 2007
Start date
Jul 1998
Primary completion
May 2007
Completion
Jun 2007
Last update
Nov 19, 2008

Study contacts

Sanz Guillermo, Dr
study chair · Hospital La Fe
Sanz Miguel Angel, Dr
principal investigator · Hospital La Fe

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion